Saied Jamshidi, MD
Neurological Surgery · Oxon Hill, MDNPI 1578648002
Payments from drug & device makers
Across 262 payments — averaging $19.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$780
- Surgentec$643
- Vivus LLC$361
- AstraZeneca$344
- Sunovion Pharmaceuticals Inc.$288
- plus $2K from 27 others
What the payments were for
- Travel & lodging$64312%
- Food & beverage$4,58488%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 83 | $1,035 |
| Novo Nordisk | 43 | $780 |
| Surgentec | 1 | $643 |
| Vivus LLC | 17 | $361 |
| AstraZeneca | 19 | $344 |
| Sunovion Pharmaceuticals Inc. | 15 | $288 |
| Pfizer | 8 | $182 |
| Alnylam Pharmaceuticals Inc. | 7 | $175 |
| Biogen | 8 | $161 |
| Teva Pharmaceuticals USA, Inc. | 6 | $160 |
| Amgen | 7 | $118 |
| UCB, Inc. | 5 | $111 |
| SK Life Science, Inc. | 3 | $96 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $83 |
| Nestle Healthcare Nutrition Inc. | 5 | $80 |
| Eisai Inc. | 3 | $75 |
| Boehringer Ingelheim | 3 | $65 |
| Sumitomo Pharma America, Inc. | 3 | $56 |
| Argenx US, Inc. | 2 | $56 |
| Biohaven Pharmaceuticals, Inc. | 3 | $55 |
| Neurocrine Biosciences, Inc. | 2 | $45 |
| Radius Health, Inc. | 2 | $40 |
| Bausch Health US, LLC | 2 | $31 |
| Ironwood Pharmaceuticals, Inc | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Boston Scientific | 1 | $23 |
| Catalyst Pharmaceuticals, Inc. | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Centinel Spine, LLC | 1 | $17 |
| Melinta Therapeutics, LLC | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION Facet Screw$643
How this compares
$5,227 in reported general payments places this provider in the 45th percentile of 133 neurological surgery providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 58 | $129,593 |
| IngrezzaValbenazine Tosylate | 11 | $89,377 |
| FarxigaDapagliflozin Propanediol | 65 | $71,577 |
| EliquisApixaban | 63 | $69,105 |
| OzempicSemaglutide | 36 | $56,930 |
| ProliaDenosumab | 28 | $47,042 |
| AptiomEslicarbazepine Acetate | 34 | $46,817 |
| LinzessLinaclotide | 35 | $36,048 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $33,122 |
| JardianceEmpagliflozin | 14 | $23,971 |
| NeuproRotigotine | 17 | $21,348 |
| MounjaroTirzepatide | 13 | $19,060 |
| TrulicityDulaglutide | 18 | $18,719 |
| TrintellixVortioxetine Hydrobromide | 22 | $12,888 |
| Keppra XrLevetiracetam | 17 | $9,097 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $780 | $186,52394 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $45 | $89,37711 claims |
| AstraZenecaFarxiga | $344 | $71,57765 claims |
| PfizerEliquis | $182 | $69,10563 claims |
| AmgenProlia | $118 | $47,04228 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $288 | $46,81734 claims |
| AbbVieLinzess, Synthroid | $1,035 | $41,60187 claims |
| Boehringer IngelheimJardiance | $65 | $23,97114 claims |
| UCB, Inc.Neupro | $111 | $21,34817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 133 neurological surgery providers in Maryland.
Other neurological surgery in Oxon Hill
- Brian SubachOxon Hill$41K
- Judy HuangBaltimore$4.2M
- Alexander CoonBaltimore$2.9M
- Faheem SandhuClinton$2M
- Charles SansurBaltimore$1.8M
- Howard EisenbergBaltimore$1.5M
- Graeme WoodworthBaltimore$1.3M
- Daniel SciubbaBaltimore$838K
- Nicholas TheodoreBaltimore$833K
- Cameron McDougallBaltimore$414K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.